Duchenne muscular dystrophy (DMD) is a lethal X-linked recessive disorder with a high spontaneous mutation rate and no effective treatment, hence development of genetic based therapies is an important goal. We report that expression of a recombinant human minidystrophin cDNA, compatible with current viral vectors, can significantly reduce the myopathic phenotype in transgenic rndx mice, even when expressed at only 20-30% of endogenous dystrophin levels at the sarcolemma. To the extent that data obtained in mouse studies are applicable to DMD, the virtual elimination of morphologiCal and biochemical abnormalities in the rndx mouse supports the use of this cDNA in somatic gene therapy protocols for DMD.
INTRODUCTION
Duchenne muscular dystrophy (DMD) is an X-linked recessive disorder with an incidence worldwide of 1 in 3,500 male births. Of these approximately one-third are due to de novo mutations in the 2.3 Mb dystrophin gene (I) . No effective treatment exists for this lethal disease, nor can it be entirely eliminated by genetic counselling; hence development of genetic based therapies is an important goal. Viral systems offer the highest efficiency gene transfer into somatic tissues but cannot accommodate the complete dystrophin cDNA (2, 3) . Some patients with very mild forms of Becker muscular dystrophy (BMD) express dystrophin mRNAs and proteins of substantially reduced size due to large in frame deletions within the DMD gene (4) . The mRNA corresponding to one such deletion of exons 1 7 4 8 has been cloned as a 6.3 kb cDNA that produces a 229 kDa protein localising to the muscle sarcolemma (5, 6) . This BMD-derived minidystrophin cDNA is sufficiently small to be accommodated by current adenoviral (2) and retroviral vectors (3) and has been successfully expressed with both systems in dystrophic rndx mouse (7) muscle in vivo. To assess the function of this recombinant protein and the quantity required for restoration of the normal muscle phenotype we have produced and examined rndx mice transgenic for the minidystrophin in comparison with transgenic mice carrying the full-length human dystrophin (8) .
RESULTS

Generation of transgenic mdr mice expressing human dystrophin
Multiple transgenic lines were produced by microinjection of dystrophin expression constructs (Fig. la) , utilising the human a-skeletal actin (HSA) (9) or the mouse M-creatine kinase (MCK) promoter (lo), into the pronuclei of single celled fertilised ova of C57BlllOXCBAlJ mice (1 I). Transgenic lines were bred onto the rndx background by mating transgenic males with rndx females, and resultant male offspring were analyzed at 6 weeks, 3 months and 6 months for transgene expression and muscle pathology. Transgenic animals were always compared to non-transgenic littermates to eliminate any effects that might be due to minor differences in the genetic background. Southern blot analysis of FI mice revealed copy numbers ranging from single copy to approximately 50 copies, with most lines being in the region of 2-5 copies. No I246 Human Molecular Genetics, 1995, Vol. 4, No. 8 in rodents (12) . Western blot analysis of microsomal fractions Immunoblot analysis of dystrophin expression in various tissues from control rndx and normal (BIO) mice and a minidystrophin transgenic mdr mouse (AB2). Skeletal muscle and heart preparations were subjected to a low speed spin to remove myofibrils as myosin interferes with detection of the minidystrophin. All other lanes were run with whole tissue homogenates. Note the presence of the Dp71 protein in the brain that is produced from a promoter downstream of the stop codon in the mdx mutation and so detected with the C-terminal antibody used on this blot (Dy816C5).
correlation between expression level and copy number was apparent and expression of transgenes from the HSA promoter was confined predominantly to skeletal muscles with additional very low expression only in the heart (Fig. I b) . Similar results were obtained with the MCK promoter.
Analysis of transgenic rndx mice
Morphological changes in the dystrophic phenotype were initially assessed by examining haematoxylin-and eosinstained sections of quadriceps from 6 week old transgenic rndx mice in comparison to their non-transgenic rndx littermates (Fig. 2a) . Expression of either the human full-length or minidystrophin cDNA was able to effectively reduce or eliminate the dystrophic pathology, as judged by differences in the central nucleation of the muscle fibres, a marker of regeneration from skeletal muscle tissues demonstrated a range of transgene expression above and below the level of endogenous dystrophin in C57B1/10 wild type mice. Even the expression of very small quantities of dystrophin produced a reduction in muscle dystrophic pathology. In lines which demonstrated normal or near-normal muscle morphology there was a corresponding decrease in serum creatine kinase to normal levels (Fig. 2b) .
Minor mismatches between the reduction in central nucleation and the serum creatine kinase levels likely reflect differences in the time of onset of any muscle necrosis relative to collection of blood samples. The degree of muscle pathology at 6 weeks of age was inversely proportional to the amount of recombinant dystrophin expressed at the muscle membrane, the latter being assessed by multiple Western blots and immunohistochemistry (Fig. 2c) . Microsomal levels of 20-30% of endogenous were sufficient to correct the primary myopathic features of rndx skeletal muscle.
The rndx mouse has been criticised as a model of DMD since in most skeletal muscles, after an initial period of intense myopathy at 2-6 weeks, there is full regeneration and a lack of the progressive fibrosis seen in DMD patients (1 3). However, the diaphragm muscle does show the progressive damage and fibrosis typical of DMD (Fig. 3a) , possibly as a consequence of its high work load in a rapidly breathing small mammal (14) . Examination of the histopathology of the diaphragm at 3 and 6 months revealed a continued protection against the dystrophic phenotype in those lines that exhibited very little or no pathology at 6 weeks (Fig. 3b,c) . In the case of full-length human dystrophin complete restoration of normal diaphragm histology has been obtained. However, with the minidystrophin transgenics occasional groups of centrally nucleated fibres have been observed at 6 months.
As previously described (6) both the human full-length and minidystrophin were localized to the sarcolemma in rndx muscle (Fig. 4 ) . Utrophin, the autosomal homologue of dystrophin, which is expressed in adult rndx muscle (15) was decreased in the transgenics to normal control levels with the expected predominant accumulation at neuromuscular junctions. Both full-length and minidystrophin transgenics also demonstrated appropriate reactivated sarcolemmal expression of the 43 and 50 kDa dystrophin associated glycoproteins (DAG) and the 59 kDa dystrophin associated protein (DAP), which indicates stabilisation of the DAG complex (16) linking sub-sarcolemmal dystrophin to laminin and the extracellular matrix (17, 18) .
While both the full-length and minidystrophin proteins are clearly associated with the sarcolemma based on immunostaining, Western blot analysis using whole muscle and microsomal extracts revealed a marked difference between the full-length and minidystrophin proteins in the efficiency of association with the muscle membrane. When minidystrophin expression was examined on the wild-type background high levels, equivalent to or greater than endogenous mouse dystrophin, were observed in the whole muscle extracts (Fig. 5a ). However, a much lower proportion of the recombinant minidystrophin purified with the microsomal fraction. This reduced association with the muscle sarcolemma was not due to species differences or competition with endogenous dystrophin as a similar relative pattern was noted when minidystrophin and 
DISCUSSION
human full-length expression were compared on the mdr Our data show that the 427 kDa protein product of the human background. Again the full-length protein was more highly full-length dystrophin cDNA can provide restoration of the concentrated in the microsomal fraction (Fig. 5b) .
normal muscle phenotype in the transgenic mdr mouse. More and full-length (AD 17) transgenic mdx mice. Dystrophin immunostains localize to the sarcolemma in the control and both transgenic mice but is absent in the mdx mouse. Similar staining patterns are obtained with antibodies to the 59 DAP, 50 and 43 DAGs. In contrast, the dystrophin related protein, utrophin, which is strongly expressed in the mdx mouse is only expressed at the neuromuscular junctions in the control and transgenic mice. Scale bar represents 50 pm.
importantly, we have also demonstrated that the 229 kDa minidystrophin product of the human BMD-derived cDNA !can provide substantial restoration of the normal muscle phenotype, including prevention of the severe fibrotic changes in the mdx diaphragm. Interestingly, expression of either protein product in the wild type background did not produce any pathology as a result of competition between transgene and endogenous dystrophin, suggesting the possibility that gene therapy using such constructs might be applicable not only to boys with DMD but also to manifesting carriers of DMD and boys with Becker muscular dystrophy. It seems likely that the minidystrophin product is less functionally effective at complementing dystrophin deficiency than that from the full-length cDNA and we have noted a relative instability in membrane association of the 229 kDa protein compared to the human 427 kDa protein. This implies it will be necessary to express higher levels of the minidystrophin relative to the full length dystrophin to achieve the same therapeutic effect. Nonetheless, as substantial protection is afforded even at low levels of minidystrophin expression at the muscle membrane, 20-30% of endogenous dystrophin, this result justifies the continued development of gene therapy protocols using currently available viral vectors that can accommodate this minidystrophin.
MATERIALS AND METHODS
Production of transgenic mice
The construct used for production of transgenic mice was assembled in pBS I1 (SK+)(Stratagene) by the following consecutive steps. A BamH I (Klenow repaired)lXhoI fragment containing the SV40 early splice region and polyadenylation signals from pMSG (Pharmacia) was cloned into the Apnl (T4 polymerase blunt ended)/ Xltol cut pBS. A Not1 linker was inserted into the pBS polylinker Kpr~ I site to provide a unique site at each end of the construct for final linear tramgenic injection fragment preparation. The dystrophin Serum creatine kinase analysis Serum creatine kinase levels were measured using the Boeh~inger NAC-CK kit and controlled for run to run variation against Precinorrn-U standard (Boehringer). The rate per minute was averaged over 10 min and calculated as U/I.
Western blot analysis For Western blot analysis 0.4 g fresh skeletal muscle from the hindlimb was prepared as previously described (12) . A low speed centrifugation was used to remove myofibrils as the position of myosin at I80 kDa may interfere with the detection of the minigene product at 229 kDa. High speed centrifugation was then used to pellet the rnicrosomal fraction. Blots were stained with amido black to confirm equality of protein load and transfer. Blots were probed with !he monoclonal antibody Dy8/6C5 which recognises an epitope at the C-terminus of dystrophin (19) . lmmunohistochemistry and histology The quadriceps of 6 week old transgenic and control mice were excised postmortem and rapidly frozen in liquid nitrogen cooled isopentane. Cryosections 7 pm thick were prepared and immunostained with affinity purified sheep polyclonal antibodies specific for dystrophin, 59 DAP, or P-dystroglycan (43 DAG) (20) , or rabbit polyclonal antibodies against DRP (21) or adhalin (50 DAG) (22) . For histological examination of muscle morphology frozen sections were cut at 7 pm and stained with haematoxylin and eosin in standard fashion. The number of centrally nucleated fibres across intact rectus femoris muscles (approximately 1500 fibres) were counted blind by two independent observers.
